In the wake of COVID-19 there has been a renewed focus on the delivery of drugs through non-traditional (non OSD) routes. Orally inhaled nasal drug products (OINDPs) have continued to emerge as a viable option for drugs with low bioavailability as well as vaccines in both humans and animals. Development of these complex formulations provides additional challenges when compared to more traditional routes of administration. This webinar is designed to outline the challenges, analytical testing, and routine troubleshooting often encountered in the OINDP space.
Speakers
- Daniel Beach - Team Leader Small Molecule Development, Malvern Panalytical
More information
Who should attend:
- Analysts working in the OINDP space, either development or quality control
- Those interested in entering the OINDP space who are seeking to better understand the challenges and testing required to bring an OINDP to market
What you will learn:
- Challenges associated with developing OINDP products, analytical considerations, and solutions
Lab to Clinic Webinar Series
The development of successful pharmaceutical drugs is a long time-consuming and expensive process. Each stage of the development workflow has unique challenges and requirements, each with it’s own analytical and characterization needs.
In this 4-part webinar series, we will cover a range of topics within the pharmaceutical development process starting with candidate selection and screening for binding kinetics, moving on to screening and controlling for API polymorphs and finishing up with the development of nasal sprays, aerosols and inhalers for drug delivery.
Throughout this series, we will highlight how technical challenges can be overcome by utilizing the appropriate analytical tools.
Want to know more?
Register for any session in our webinar series - and keep an eye out for the recordings afterwards too!
- Orthogonal technologies for candidate selection - June 27th
- Rapid screening for binding kinetics - July 11
- Screening and Controlling API Polymorphs - July 25